THX Pharma Enters Strategic Licensing Agreement with Biocodex
THX Pharma has signed a strategic licensing agreement with the pharmaceutical group Biocodex for the development and commercial exploitation of two drug candidates. This agreement represents a total amount that could reach €173 million.
The agreement between THX Pharma and Biocodex encompasses the global development and commercial exploitation of Batten-1, as well as TX01 in the United States and Canada. Batten-1 targets the juvenile form of Batten disease. TX01 is a new formulation intended for the treatment of Gaucher's disease and Niemann-Pick type C disease.
Additional Information
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Broader Collaborations
TX01 is already subject to several licensing agreements with international pharmaceutical partners such as Exeltis and Biocodex for its development and commercialization in various regions of the world. THX Pharma is a biopharmaceutical company specialized in the development of innovative treatments for rare neurological diseases, listed on the Euronext Growth market in Paris.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Context
Period
Period: 2025
Key reported figures
Revenue: 813K€
Net income: -3 002 k€
Guidance from the release
L'accord stratégique récemment conclu avec Biocodex,...
THX Pharma renforce sa solidité financière.
Risks mentioned
Pression sur les coûts de développement liée aux essais cliniques.
Incertitude réglementaire sur les projets de commercialisation.
Opportunities identified
Lancement clinique de TX01 et Batten-1 en 2026.
Accord stratégique avec Biocodex.
Visibilité financière sécurisée avec Biocodex.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
